Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04899310
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT04860297
- Locations
- 🇺🇸
Aventiv Research Inc, Mesa, Arizona, United States
🇺🇸California Institute of Renal Research, San Diego, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1283Biological: mRNA-1273Biological: Placebo
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04813796
- Locations
- 🇺🇸
Synexus Clinical Research US Phoenix Southeast, Inc., Chandler, Arizona, United States
🇺🇸Optimal Research San Diego, LLC, San Diego, California, United States
🇺🇸Optimal Research Melbourne, LLC, Melbourne, Florida, United States
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
- Conditions
- SARS-CoV-2
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 11942
- Registration Number
- NCT04796896
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸MedPharmics, LLC, Albuquerque, New Mexico, United States
🇺🇸Emmaus Research Center Inc, Anaheim, California, United States
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
- Conditions
- SARS-CoV-2
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 4331
- Registration Number
- NCT04649151
- Locations
- 🇺🇸
Velocity Clinical Research - Banning, Banning, California, United States
🇺🇸Paradigm Clinical Research, La Mesa, California, United States
🇺🇸Altus Research - Hunt - PPDS, Lake Worth, Florida, United States
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Biological: mRNA-1345Drug: Placebo
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 651
- Registration Number
- NCT04528719
- Locations
- 🇺🇸
Paradigm Clinical Research Institute Inc - ClinEdge - PPDS, La Mesa, California, United States
🇺🇸Mills Clinical Research, West Hollywood, California, United States
🇺🇸Accel Research Site - Angel Kids Pediatrics - ERN - PPDS, DeLand, Florida, United States
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273Biological: Placebo
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 30415
- Registration Number
- NCT04470427
- Locations
- 🇺🇸
Ascension St. Vincent Birmingham, Birmingham, Alabama, United States
🇺🇸Synexus Clinical Research US, Inc. - Birmingham, Birmingham, Alabama, United States
🇺🇸Hope Research Institute, Phoenix, Arizona, United States
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273.351Biological: Placebo
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 660
- Registration Number
- NCT04405076
- Locations
- 🇺🇸
Meridian Clinical Research, Dakota Dunes, South Dakota, United States
🇺🇸Alliance for Multispecialty Research, Kansas City, Missouri, United States
🇺🇸Trial Management Associates, Wilmington, North Carolina, United States
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
- Conditions
- Cytomegalovirus Infection
- Interventions
- Other: PlaceboBiological: mRNA-1647
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT04232280
- Locations
- 🇺🇸
Benchmark Research, Sacramento, California, United States
🇺🇸Optimal Research, Peoria, Illinois, United States
🇺🇸Johnson County Clin-Trials, Lenexa, Kansas, United States
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04159103
- Locations
- 🇯🇵
Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
🇯🇵Tohoku University Hospital, Sendai-Shi, Miyagi, Japan
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States